Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (JNJ) announced promising Phase 1 trial results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody for treating relapsed or refractory multiple myeloma. The trial showed an impressive 86.1% overall response rate among 36 patients at the recommended Phase 2 dose, with 100% response in BCMA and GPRC5D therapy-naive patients. JNJ-5322 uniquely targets three distinct proteins: BCMA and GPRC5D on myeloma cells and CD3 on T-cells. The study involved 126 patients with 8.2 months median follow-up. While cytokine release syndrome occurred in 59% of patients, no cases were Grade 3 or higher. However, 28% experienced Grade 3+ infections, and four treatment-related deaths were reported, including one from adenoviral encephalitis.

Johnson & Johnson announced groundbreaking long-term data for CARVYKTI in treating relapsed/refractory multiple myeloma. The CARTITUDE-1 study showed 33% of patients (32 out of 97) achieved progression-free survival of 5+ years with just a single infusion, requiring no maintenance therapy. The median overall survival reached 60.7 months, with 12 patients maintaining minimal residual disease negativity throughout the five-year follow-up. The safety profile remained consistent with no new safety signals, except for two new solid tumor cases. Additional CARTITUDE-4 study data demonstrated CARVYKTI's superior progression-free and overall survival benefits across various patient subgroups, including those with standard and high-risk cytogenetics.

Johnson & Johnson announced impressive clinical trial results for DARZALEX FASPRO in multiple myeloma treatment. The Phase 3 PERSEUS study showed 95.3% progression-free survival at 48 months in transplant-eligible patients, with over 55.8% achieving sustained MRD negativity for 24+ months using DARZALEX FASPRO-based regimen (D-VRd) followed by D-R maintenance. The Phase 3 CEPHEUS study in transplant-ineligible patients demonstrated 60.4% overall MRD negativity and 69% progression-free survival at 54 months with D-VRd treatment. The drug showed significant improvements over standard treatments across multiple efficacy measures, with consistent safety profiles, positioning DARZALEX FASPRO as a cornerstone therapy for newly diagnosed multiple myeloma patients.

Johnson & Johnson announced breakthrough results from Phase 3 AMPLITUDE study evaluating AKEEGA® (niraparib and abiraterone acetate) combination therapy in metastatic castration-sensitive prostate cancer (mCSPC) patients with HRR genetic alterations. The study demonstrated a 48% reduction in disease progression risk for BRCA-altered patients and 37% reduction for HRR-altered patients. The treatment showed significant improvements in radiographic progression-free survival (rPFS) and delayed symptom progression. In BRCA-altered patients, median rPFS was not reached compared to 26 months with placebo. The combination also showed an early trend toward improved overall survival. While Grade 3/4 adverse events were more frequent in the treatment group (75% vs 59%), discontinuation rates remained low at 14.7%. This marks the first Phase 3 data showing clinical improvement with a PARP-based combination in mCSPC.

Johnson & Johnson (NYSE: JNJ) has scheduled an investor conference call to discuss its second-quarter 2025 results on Wednesday, July 16th at 8:30 a.m. (Eastern Time). The call will be hosted by key executives including CEO Joaquin Duato, CFO Joseph J. Wolk, and VP of Investor Relations Darren Snellgrove.

Investors can access the call via webcast at www.investor.jnj.com or by telephone (U.S.: 877-869-3847, International: 201-689-8261). The earnings press release will be available at 6:45 a.m. ET on the day of the call. A replay will be accessible until July 30th. The company has also announced its third-quarter earnings call date for October 14th, 2025.

Jessica Dean, partner at Dean Omar Branham Shirley, LLP, has been named to The National Law Journal's 2025 Elite Women of the Plaintiffs Bar. Dean has established a notable reputation for challenging major corporations, particularly Johnson & Johnson (NYSE: JNJ) in recent years. Her significant achievements include securing a $45 million verdict in 2024 for the Garcia family against JNJ in Chicago. The case faced delays due to JNJ's attempts to use bankruptcy proceedings to avoid liability. Dean's recognition extends to being listed in Lawdragon's 500 Leading Lawyers in America and 500 Leading Plaintiff Consumer Lawyers lists. Her work has resulted in substantial compensation for victims and families affected by corporate negligence.

An FDA expert panel has called for new standards to ban talc use in consumer products including gum, candy, rice, and pharmaceuticals. The panel cited over 30 years of studies linking talc to ovarian cancer, which previously led Johnson & Johnson (JNJ) to discontinue its talc-based body powders. Dr. George Tidmarsh from Stanford University emphasized talc's carcinogenic nature, while Dr. Daniel Cramer's 1982 study showed an 82% increased risk of ovarian cancer in women regularly using talc-based powders. The National Institutes of Health and International Agency for Research on Cancer have recently upgraded talc's cancer risk classification from "possible" to "probable." Multiple tests, including FDA's own, have detected asbestos in cosmetic talc, further elevating cancer risks.

Johnson & Johnson (NYSE: JNJ) has announced its participation in Bernstein's 41st Annual Strategic Decisions Conference scheduled for May 28th, 2025. The company's management will engage in a Fireside Chat at 9:00 a.m. Eastern Time. Investors and interested parties can access a live audio webcast of the presentation through J&J's Investor Relations website. An archived version of the session will be made available approximately 48 hours after the webcast.

Johnson & Johnson (NYSE: JNJ) received a favorable vote (6-2) from the FDA's Oncologic Drugs Advisory Committee for DARZALEX FASPRO® in treating high-risk smoldering multiple myeloma (HR-SMM). Based on the Phase 3 AQUILA study, the treatment showed positive progression-free survival benefits. If approved, it would become the first approved treatment for HR-SMM, potentially preventing progression to active multiple myeloma. Currently, about 15% of newly diagnosed multiple myeloma cases are classified as smoldering, with 50% of HR-SMM patients likely to develop active disease within 2-3 years. The current standard of care is only active monitoring until progression. The FDA application was submitted in November 2024, and while the ODAC recommendation is non-binding, it represents a significant step toward potential approval.